More recently, encouraging clinical results from a triple-hormone-receptor agonist, Retatrutide, and several GLP-1R/GCGR dual agonists, suggest that GCGR could be a promising co-stimulating target for type 2 diabetes and obesity.
GLP-1based agents such as semaglutide and tirzepatide are now widely studied in laboratory models of obesity and chronic disease
One study showed that it works longer. So, if youve hit a weight loss wall on semaglutide, it makes sense to ask your doctor about other options
Clays and carbons are natural binders to assist the body in eliminating these toxins from the digestive tract
Lately, Ive been getting a lot of questions about NAD+what it is, what it does, and whether its worth trying in IV therapy